Peter Li
Hematology & Oncology · Fort Sam Houston, TXNPI 1942709647
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 67 payments — averaging $42.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$361
- Karyopharm Therapeutics Inc.$250
- AbbVie$234
- Amgen$187
- Gilead$167
- Sobi, Inc$156
- plus $2K from 28 others
What the payments were for
- Food & beverage$2,878100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 5 | $361 |
| Karyopharm Therapeutics Inc. | 6 | $250 |
| AbbVie(2 entities) | 3 | $234 |
| Amgen | 6 | $187 |
| Gilead | 2 | $167 |
| Sobi, Inc | 2 | $156 |
| Apellis Pharmaceuticals, Inc. | 1 | $136 |
| Boehringer Ingelheim | 2 | $134 |
| Genmab U.S., Inc. | 1 | $133 |
| Tempus AI, Inc | 1 | $121 |
| Cardiovascular Systems Inc. | 1 | $107 |
| AstraZeneca(2 entities) | 5 | $97 |
| Tactile Systems Technology Inc | 1 | $94 |
| Incyte Corporation | 4 | $81 |
| Mirati Therapeutics, Inc. | 3 | $76 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $62 |
| Bristol Myers Squibb | 2 | $46 |
| Recordati_rare_diseases_inc. | 2 | $46 |
| Ipsen Biopharmaceuticals, Inc | 2 | $43 |
| AVEO Pharmaceuticals, Inc. | 2 | $42 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Tersera Therapeutics LLC | 1 | $26 |
| Exelixis Inc. | 1 | $25 |
| GSK | 1 | $25 |
| Coherus Oncology, Inc. | 1 | $23 |
| Immunogen, Inc. | 1 | $23 |
| Rigel Pharmaceuticals, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Morphosys, US Inc. | 1 | $22 |
| ADC Therapeutics America, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| CTI Biopharma Corp. | 1 | $19 |
| Medtronic | 1 | $15 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SARCLISA$246
- Empaveli$136
- DOPTELET$133
- EPKINLY$133
- XPOVIO$129
- DALVANCE$120
- Kyprolis$116
- JARDIANCE$112
- Peripheral Orbital Atherectomy System$107
- Coronary Orbital Atherectomy System$107
How this compares
$2,878 in reported general payments places this provider in the 45th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Fort Sam Houston
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.